Trutek Corp. v. BlueWillow Biologics: Federal Circuit Appeal Voluntarily Dismissed
Trutek Corp. appealed against BlueWillow Biologics, Inc. over four patents covering nasal antiseptic compositions, targeting the NanoBio® Protect Nasal Antiseptic Solution. After 266 days, the parties filed a joint stipulation of dismissal at the Federal Circuit — each side bearing its own costs, with no merits ruling issued.
Nasal antiseptic patent appeal ends by joint stipulation before merits ruling
Trutek Corp., holder of four patents covering nasal antiseptic compositions and related formulations, brought this appeal at the Court of Appeals for the Federal Circuit (Case No. 24-1555), targeting BlueWillow Biologics, Inc. and its NanoBio® Protect Nasal Antiseptic Solution. The case was filed on 11 March 2024, originating as an infringement action before reaching the Federal Circuit on appeal.
On 2 December 2024, the parties filed a joint stipulation of dismissal under Federal Rule of Appellate Procedure 42(b)(1), which the court accepted by order. The appeal was dismissed with each party bearing its own costs, and a pending motion at ECF No. 56 was withdrawn. The basis of termination is recorded as voluntary dismissal, and the public record does not specify whether dismissal was with or without prejudice at the underlying district court level.
The 266-day duration suggests the parties reached an agreement — or mutual decision to disengage — before full appellate adjudication. The symmetric cost allocation and joint nature of the stipulation are consistent with a negotiated resolution or commercial decision to cease litigation, though the precise terms of any underlying arrangement are not disclosed in the public record. Whether Trutek retains the ability to reassert these patents in future proceedings remains an open question.
Filing to Voluntary dismissal in 266 days
266 days — resolved before full appellate briefing cycle typically concludes
Appeal voluntarily dismissed: what the joint stipulation means for both parties
FRAP 42(b)(1) joint stipulation: appeal ends without merits ruling
Under Federal Rule of Appellate Procedure 42(b)(1), parties to an appeal may jointly stipulate to dismiss the case. The Federal Circuit accepted the stipulation and issued an order of dismissal on 2 December 2024. Critically, no substantive ruling on the four asserted patents was issued — the appellate court did not assess validity, infringement, or claim scope. The underlying district court record remains the last merits-level adjudication.
No merits ruling issuedWith or without prejudice? The public record is silent
A voluntary dismissal under FRAP 42(b)(1) can, in principle, leave open the question of whether claims may be refiled. The order specifies dismissal of the appeal and cost allocation but does not expressly state ‘with prejudice’ or ‘without prejudice.’ The public record therefore does not allow a definitive conclusion on Trutek’s ability to reassert these patents in a future infringement action against BlueWillow or other parties.
Prejudice status undisclosedTrutek exits appeal with no adverse appellate ruling on its patents
Trutek Corp. did not obtain an appellate ruling affirming any infringement finding, but equally received no adverse judgment invalidating its patents. The four asserted patents — covering nasal antiseptic compositions — remain formally intact as issued patents. However, the failure to secure a merits decision limits the precedential value of this litigation for future enforcement efforts against other potential infringers.
Patents remain unchallenged on appealSymmetric cost allocation signals mutual interest in resolution
The joint stipulation with each party bearing its own costs typically signals a negotiated exit rather than a unilateral concession. For the nasal antiseptic and antimicrobial formulation sector, this outcome leaves the competitive landscape largely unchanged from a patent-rights perspective. Companies operating adjacent to NanoBio® Protect technology or Trutek’s formulation claims should monitor any future re-filing activity or licensing approaches by Trutek.
Watch for future enforcement activityFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Trutek, Corp. | Company | Nasal antiseptic IP licensor — holder of US8163802B2 and three related formulation patentsSearch in Eureka ↗ |
| Defendant | BlueWillow Biologics, Inc. | Company | BlueWillow Biologics, Inc. — developer of NanoBio® Protect Nasal Antiseptic SolutionSearch in Eureka ↗ |
| Plaintiff counsel | Stanley H. Kremen | Attorney | Counsel for Trutek, Corp.Search in Eureka ↗ |
| Plaintiff law firm | Patents Group LLC | Law Firm | Representing Trutek, Corp.Search in Eureka ↗ |
| Defendant counsel | Bradley Roush | Attorney | Counsel for BlueWillow Biologics, Inc.Search in Eureka ↗ |
| Defendant counsel | Liane M. Peterson | Attorney | Counsel for BlueWillow Biologics, Inc.Search in Eureka ↗ |
| Defendant counsel | Molly Freas Hayssen | Attorney | Counsel for BlueWillow Biologics, Inc.Search in Eureka ↗ |
| Defendant law firm | Foley & Lardner, LLP | Law Firm | Representing BlueWillow Biologics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order accepts a joint stipulation under FRAP 42(b)(1) and dismisses the appeal with symmetric cost allocation. The phrasing is strictly procedural — the Federal Circuit made no finding on infringement, validity, or claim construction of the four asserted patents. The withdrawal of ECF No. 56 and denial of other motions as moot confirms the court closed all pending matters without substantive adjudication. For both parties, the absence of a merits ruling means no appellate precedent was created and no estoppel necessarily attaches at the appellate level from this proceeding.
US8163802B2 — nasal antiseptic compositions and antimicrobial formulations
The four asserted patents — US8163802B2, US5468488A, US6844005B2, and US5674481A — collectively cover formulations and compositions in the nasal antiseptic and topical antimicrobial space. The application dates span multiple decades, suggesting a long-held portfolio that Trutek has actively sought to enforce. The patents appear to cover compositional and method claims relevant to intranasal antiseptic delivery, the technical domain directly implicated by BlueWillow’s NanoBio® Protect product.
From a competitive intelligence perspective, a four-patent assertion against a single commercial product is consistent with a portfolio enforcement strategy designed to maximise licensing leverage and complicate design-around options. For companies developing nasal antiseptic, intranasal drug delivery, or mucosal antimicrobial products, Trutek’s portfolio represents a latent risk — particularly given that no court has invalidated any of the four patents on the merits in this proceeding. The longevity of some patents in the portfolio also suggests proximity to expiry for the oldest titles, which may affect the commercial calculus of future enforcement.
Should you run an FTO against US8163802B2 and Trutek’s nasal antiseptic portfolio?
Any R&D team developing nasal antiseptic solutions, intranasal antimicrobial sprays, or mucosal delivery formulations should treat Trutek’s four-patent portfolio as an active FTO consideration. The voluntary dismissal of this appeal provides no legal clearance — the patents remain in force and their claim scope has not been adjudicated at the Federal Circuit. Products adjacent to the NanoBio® Protect technology profile are particularly exposed.
PatSnap Eureka’s FTO Search Agent allows you to map claim scope across all four Trutek patents simultaneously, identify relevant prior art that could support validity challenges, and benchmark your product’s formulation against the claim language. For teams at the formulation or preclinical stage of intranasal products, running this analysis now is significantly less costly than responding to an enforcement action post-launch.
Run a freedom-to-operate analysis on US8163802B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in nasal antiseptic and antimicrobial formulation IP
Explore comparable Federal Circuit infringement appeals involving nasal antiseptic, intranasal antimicrobial, and topical formulation patents to benchmark litigation risk and strategy.
What this case signals for the nasal antiseptic and antimicrobial formulation IP landscape
A four-patent Federal Circuit appeal resolved by joint stipulation raises pointed questions for competitors and licensees in the nasal antiseptic space.
No precedent set: Trutek’s four patents remain available for future enforcement
Because the Federal Circuit issued no merits ruling, the four asserted patents covering nasal antiseptic compositions are neither affirmed nor invalidated at the appellate level. Any company marketing nasal antiseptic or intranasal antimicrobial products should assess exposure to these patents independently — the litigation outcome provides no safe harbour.
Joint stipulations at the Federal Circuit often signal commercial resolution
FRAP 42(b)(1) joint stipulations are typically the product of settlement negotiations or a mutual commercial decision to stand down. The symmetric cost term reinforces this reading. IP professionals monitoring this space should note that undisclosed licensing terms or product changes may have driven the exit, and such terms are not part of the public record.
Trutek v BlueWillow — key questions answered
The Federal Circuit appeal was voluntarily dismissed on 2 December 2024 via a joint stipulation under FRAP 42(b)(1). Both parties agreed to dismiss with each bearing its own costs. No merits ruling on the four asserted nasal antiseptic patents was issued. The appeal had been filed on 11 March 2024 and ran for 266 days.
Trutek asserted four patents: US8163802B2, US5468488A, US6844005B2, and US5674481A. All relate to nasal antiseptic and antimicrobial formulation technology. The accused product was BlueWillow’s NanoBio® Protect Nasal Antiseptic Solution. The patents span a multi-decade filing history, suggesting a broad portfolio enforcement strategy.
No. A voluntary dismissal under FRAP 42(b)(1) is a procedural termination with no merits adjudication. None of the four Trutek patents were ruled invalid or unenforceable by the Federal Circuit. The patents remain formally in force, and Trutek’s ability to assert them in future proceedings has not been extinguished by this dismissal.
The joint stipulation specified that neither party would recover appellate costs from the other. This symmetric allocation is standard in jointly stipulated dismissals and typically reflects a negotiated exit rather than a one-sided concession. It does not indicate who was in a stronger or weaker legal position, and no attorney fees award was made.
NanoBio® Protect is an intranasal antiseptic solution developed by BlueWillow Biologics based on its proprietary nanoemulsion platform. Trutek alleged that the product infringed its portfolio of nasal antiseptic formulation patents. The Federal Circuit dismissed the appeal before any ruling on infringement, so no court has adjudicated whether the product actually infringes any of the four asserted patents.
PatSnap Eureka searches patents and litigation data to answer instantly.